Stemline Therapeutics Reports Third Quarter 2016 Financial Results and Highlights Recent Regulatory and Clinical Progress

November 8, 2016 at 7:00 AM EST

NEW YORK, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended September 30, 2016.

Ivan Bergstein, M.D., Stemline's Chief Executive Officer, commented, "A key highlight of the quarter was the FDA granting SL-401 Breakthrough Therapy designation for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a deadly malignancy of the immune system of unmet medical need. We also continue to make significant progress across our entire pipeline, resulting in seven presentations, including an oral presentation of updated Phase 2 trial results of SL-401 in BPDCN, at the upcoming American Society of Hematology (ASH) annual meeting."

Dr. Bergstein concluded, "We look forward to gaining further clarity around our BPDCN registration pathway and timelines in the near-term, and have begun to build-out our pre-commercial infrastructure in preparation for success. Importantly, our strong cash position provides us with the resources to reach important clinical, regulatory and commercial milestones across our many programs."

Third Quarter 2016 Financial Results Review
Stemline ended the third quarter of 2016 with $74.3 million in cash, cash equivalents and investments, as compared to $81.2 million as of June 30, 2016, which reflects a cash burn of $6.9 million for the quarter.

For the third quarter of 2016, Stemline had a net loss of $9.9 million, or $0.56 per share, compared with a net loss of $9.2 million, or $0.53 per share, for the same period in 2015.

Research and development expenses were $7.2 million for the third quarter of 2016, which reflects a decrease of $0.1 million, or 2%, compared with $7.3 million for the third quarter of 2015.

General and administrative expenses were $3.2 million for the third quarter of 2016, which reflects an increase of $1.0 million, or 43%, compared with $2.2 million for the third quarter of 2015. The increase in expense was primarily attributable to higher non-cash stock based compensation and payroll costs relating to employees.

About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics. Stemline is developing three clinical stage product candidates, SL-401, SL-801, and SL-701. SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a wide range of malignancies. SL-401 is being advanced through a potentially pivotal Phase 2 trial in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an indication for which SL-401 has been granted Breakthrough Therapy Designation (BTD) by the FDA. SL-401 has demonstrated high overall response rates (ORR), with multiple complete responses (CRs), in both first-line and relapsed refractory patients, and response-driven outcomes including treatment duration and frequency of bridge to transplant have been trending favorably. SL-401 is also being advanced through Phase 1/2 trials of patients with additional malignancies including acute myeloid leukemia (AML) in remission with minimal residual disease (MRD), high risk myeloproliferative neoplasms (MPN), and relapsed/refractory multiple myeloma (in combination with pomalidomide). SL-801 is a novel oral small molecule reversible inhibitor of XPO1 that has demonstrated broad in vivo and in vitro preclinical activity in a wide array of solid and hematologic malignancies. A Phase 1 trial with SL-801 is open and enrolling patients with advanced solid tumors, and a Phase 1 trial in hematologic malignancies is planned. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. A Phase 2 trial with SL-701 in adult patients with second-line glioblastoma multiforme (GBM) is ongoing. For more information about Stemline Therapeutics, please visit

Forward-Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: the success and timing of our clinical trials and preclinical studies for our product candidates, including site initiation, internal review board approval, scientific review committee approval, patient accrual, safety, tolerability and efficacy data observed, and input from regulatory authorities; our plans to develop and commercialize our product candidates; our available cash and investments; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to manufacture; the performance of third-party manufacturers, clinical research organizations, clinical trial sponsors and clinical trial investigators; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Table 1. Stemline Therapeutics, Inc. - Balance Sheets

  September 30, 2016
 December 31, 2015 
Current assets:     
Cash and cash equivalents  $9,127,991 $13,376,196 
Short-term investments 41,375,137 32,663,245 
Prepaid expenses and other current assets 523,612 651,889 
Total current assets 51,026,740 46,691,330 
Furniture and fixtures, net 23,482 95,661 
Long-term investments 23,818,645 51,428,632 
Other Assets 212,305  
Total assets $75,081,172 $98,215,623 

Liabilities and stockholders' equity
Current liabilities:     
Accounts payable and accrued expenses $7,917,969 $8,632,873 
Current portion of deferred grant revenue  1,197,600  822,604 
Total current liabilities 9,115,569 9,455,477 
Deferred grant revenue, net of current portion  616,949 
Other liabilities 159,975 31,241 
Total liabilities 9,275,544 10,103,667 
Stockholders' equity:     
Preferred stock $0.0001 par value, 5,000,000 shares authorized, none issued and outstanding at September 30, 2016 and December 31, 2015   
Common stock $0.0001 par value, 33,750,000 shares authorized at September 30, 2016 and December 31, 2015. 19,151,652 shares issued and outstanding at September 30, 2016 and 18,235,020 shares issued and outstanding at December 31, 2015 1,916 1,825 
Additional paid-in capital 191,584,735 185,703,423 
Accumulated other comprehensive loss (47,512)(153,690)
Accumulated deficit (125,733,511)(97,439,602)
Total stockholders' equity 65,805,628 88,111,956 
Total liabilities and stockholders' equity $75,081,172 $98,215,623 


Table 2. Stemline Therapeutics, Inc. - Statements of Operations (Unaudited)

 Three Months Ended September 30,  Nine Months Ended September 30, 
  2015  2016
Grant revenue$299,401  $205,651  $741,953  $448,509 

Operating expenses:
Research and development 7,176,960   7,340,859   20,585,659   21,575,743 
General and administrative 3,187,869   2,234,991   8,914,630   6,197,694 
Total operating expenses 10,364,829   9,575,850   29,500,289   27,773,437 
Loss from operations (10,065,428)  (9,370,199)  (28,758,336)  (27,324,928)
Other income 1,378     11,736   1,609 
Interest income 132,006   137,123   417,113   259,064 
Net loss before income taxes (9,932,044)  (9,233,076)  (28,329,487)  (27,064,255)
Income tax benefit 8,822     35,578   

Net loss
$(9,923,222) $(9,233,076) $(28,293,909) $(27,064,255)
Net loss per common share:           
Basic and Diluted$(0.56) $(0.53) $(1.59) $(1.57)
Weighted-average shares outstanding:

Basic and Diluted
 17,831,022   17,515,895   17,777,675   17,196,840 
Investor Relations
Stemline Therapeutics, Inc.
750 Lexington Avenue
Eleventh Floor
New York, NY 10022
Tel: 646-502-2307